2020
Quality‐Adjusted Life‐Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis
Losina E, Silva GS, Smith KC, Collins JE, Hunter DJ, Shrestha S, Messier SP, Yelin EH, Suter LG, Paltiel AD, Katz JN. Quality‐Adjusted Life‐Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis. Arthritis Care & Research 2020, 72: 1349-1357. PMID: 31350803, PMCID: PMC6982563, DOI: 10.1002/acr.24035.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansMaleMiddle AgedModels, BiologicalOsteoarthritisQuality-Adjusted Life YearsSedentary BehaviorUnited StatesConceptsKnee osteoarthritisCases of cancerPhysical activityPhysical inactivityUS populationCardiovascular diseasePA levelsQuality-adjusted life year (QALY) lossBlack Hispanic womenHealth benefitsInsufficient physical activityQuality-adjusted life yearsLife-year lossHigher PA levelsRace/ethnicityDiabetes mellitusHispanic womenOsteoarthritisQALY lossLife yearsOsteoarthritis InitiativeLoss burdenDisease controlImproved healthActivity levels
2019
Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis. PLOS ONE 2019, 14: e0219068. PMID: 31247009, PMCID: PMC6597104, DOI: 10.1371/journal.pone.0219068.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioImmediate ARTImmediate ART initiationART initiationBudget impactLife expectancyImmediate antiretroviral therapy initiationDecrease HIV transmissionLate ART initiationModest budget impactAntiretroviral therapy initiationMedical resource useCost-effectiveness ratioCost-effectiveness analysisTherapy initiationHIV infectionHIV transmissionCôte d'IvoireART costsART efficacySTART trialCare budgetCD4CareOutcomes
2016
The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.
Walensky RP, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, Paltiel AD. The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. Annals Of Internal Medicine 2016, 165: 325-33. PMID: 27240120, PMCID: PMC5012932, DOI: 10.7326/m16-0799.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsChild, OrphanedCost-Benefit AnalysisHealth Care CostsHIV InfectionsHumansMass ScreeningModels, BiologicalSouth AfricaConceptsOverall virologic suppressionVirologic suppressionHIV transmissionYears of lifeMaternal orphansTarget strategyHIV/AIDS 90HIV case detectionIncremental cost-effectiveness ratioJoint United Nations ProgrammeHIV transmission ratesSouth African HIVCost of careCost-effectiveness ratioBase-case analysisAIDS 90Incident infectionsAfrican HIVUnited Nations ProgrammeCase detectionHIV detectionTreatment targetsSouth African survey dataRapid treatmentSocietal perspective
2011
Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department
Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, Katz JN, Losina E. Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department. PLOS ONE 2011, 6: e25575. PMID: 22022415, PMCID: PMC3192047, DOI: 10.1371/journal.pone.0025575.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioUndiagnosed HIV prevalenceEmergency department settingCost-effectiveness ratioHIV prevalenceDepartment settingScreening modalityRandomized clinical trialsResource utilization dataRoutine HIVHIV screeningHIV counselorsEmergency departmentScreening servicesClinical trialsCapacity of providersScreening programED staffHIVTest offerLife yearsUtilization dataRapid pointPrevalence
2009
Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis
Suter LG, Fraenkel L, Losina E, Katz JN, Gomoll AH, Paltiel AD. Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis. Arthritis & Rheumatism 2009, 61: 1531-1538. PMID: 19877094, PMCID: PMC2804854, DOI: 10.1002/art.24893.Peer-Reviewed Original ResearchConceptsArthroscopic partial meniscectomyMeniscal tearsKnee painInternational Knee Documentation Committee scoreMagnetic resonance imaging (MRI) indicatorsObtainable clinical informationDegenerative meniscal tearsIndividuals ages 45Mean incremental gainIKDC scoreNonoperative managementAge 45Preoperative informationPartial meniscectomyClinical informationOsteoarthritisPainTearsLower likelihoodHigher likelihoodAlternative thresholdsMedical decisionsScoresIncremental gainPatients
2008
Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival
Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival. The Journal Of Infectious Diseases 2008, 197: 1324-1332. PMID: 18422445, PMCID: PMC2423492, DOI: 10.1086/587184.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyEligible human immunodeficiency virusEffective antiretroviral therapyHuman immunodeficiency virusNeed of therapyHIV infectionImmunodeficiency virusPatient outcomesAdult cohortDeath rateART scaleTherapyCumulative deathsTreatment slotsDeathRapid scaleHIVPatientsCohortInfectionMortality
2007
Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries
Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 78-90. PMID: 17589368, PMCID: PMC3570247, DOI: 10.1097/qai.0b013e31812506fd.Peer-Reviewed Original ResearchConceptsEffective HIV vaccineHIV prevalenceHIV vaccineCondom useHIV infectionRisk behaviorsFuture HIV prevalenceTotal HIV infectionsHeterosexual HIV epidemicSuccessful vaccination campaignsRisk behavior changeVaccination statusMiddle-income countriesVaccinated individualsVaccination coverageDisease stageVaccine efficacyHIV epidemicVaccination scenariosVaccination campaignHigh riskAdult populationVaccinePrevalenceInfection
2006
The Survival Benefits of AIDS Treatment in the United States
Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The Survival Benefits of AIDS Treatment in the United States. The Journal Of Infectious Diseases 2006, 194: 11-19. PMID: 16741877, DOI: 10.1086/505147.Peer-Reviewed Original ResearchConceptsSurvival benefitAntiretroviral therapyPotent combination antiretroviral therapyPneumocystis jiroveci pneumonia prophylaxisHIV disease treatmentImmunodeficiency syndrome careOpportunistic infection prophylaxisTotal survival benefitUntreated HIV diseaseCombination antiretroviral therapyEffective antiretroviral therapyPrevention of motherAbsence of treatmentYears of lifePneumonia prophylaxisChild transmissionInfant infectionAdult patientsHIV diseaseInfection prophylaxisDisease careNew diagnosisAIDS treatmentProphylaxisSurvival increase
2005
Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients
Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. Antiviral Therapy 2005, 10: 41-52. PMID: 15751762, DOI: 10.1177/135965350501000102.Peer-Reviewed Original ResearchConceptsCD4 cell countQuality-adjusted life yearsHIV RNA monitoringAntiretroviral therapy initiationIncremental CE ratioCell countAntiretroviral therapyTherapy initiationTreatment thresholdCD4 cell count thresholdCD4 cells/mm3Initial clinical presentationCells/mm3Log10 copies/Incremental clinical benefitLife expectancyQuality-adjusted life expectancyHIV simulation modelHypothetical clinical settingsMore frequent monitoringCost-effectiveness analysisCell count thresholdAntiretroviral initiationVirological predictorsHIV RNA
2001
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectivenessPreevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction
1997
The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients
Scharfstein JA, Paltiel AD, Freedberg KA. The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients. Medical Decision Making 1997, 17: 373-381. PMID: 9343795, DOI: 10.1177/0272989x9701700402.Peer-Reviewed Original Research